secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001789769-26-000018
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio discontinues AXN-2510, pivots to acquisitions; cash $76.3M
---------------------------------------------------------------------

- Discontinued clinical development of AXN-2510; terminated license with ImmuneOnco.
- Cash, equivalents & marketable securities $76.3M as of Dec 31, 2025, down from $115.1M year-end 2024.
- Management evaluating acquisitions and in-licensing opportunities across therapeutic areas.
- Net loss per share (GAAP) $1.21 for Q4 2025; full year net loss $10.70 per share.
- Cash expected to fund operating plan beyond 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976926000018/0001789769-26-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976926000018/til-20260327.htm
  HTML page:      https://secwatch.observer/filing/0001789769-26-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer